Italfarmaco SpA :* LA COMMISSION EUROPÉENNE APPROUVE DUVYZAT POUR LE TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE DE DUCHENNE Texte ...

Regenxbio a annoncé jeudi que les nouvelles données intermédiaires d'un essai de phase I/II de son traitement expérimental RGX-202 par thérapie génique contre la dystrophie musculaire ...

Vendredi, les analystes de Scotiabank ont relevé la note de l’action Sarepta Therapeutics (NASDAQ: SRPT) de Secteur Perform à Secteur Outperform. Les analystes ont maintenu un objectif de cours de 80€ ...

CAMBRIDGE, Massachusetts - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) a annoncé que son vecteur viral rAAVrh74, utilisé dans la thérapie génique expérimentale SRP-9003 pour la dystrophie musculaire des ...

The approval is based on Phase 3 EPIDYS trial data that demonstrated meaningful treatment benefits in ambulant patients ...

Cependant, près de 50% des myopathes de type Duchenne conservent de rares fibres musculaires synthétisant la dystrophine.

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...

Pfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy targets. Pfizer has been evaluating domagrozumab under the codename PF ...

She is on the PhD programme at the Centre for Congenital Muscular Disorders, where she studies Norwegian patients with Duchenne muscular dystrophy who are under the age of 18. The author has completed ...

Inherited retinal diseases (IRDs) have been in the front line of gene therapy development for the last decade, providing a useful platform to test novel therapeutic approaches. More than 40 clinical ...